Compare REED & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | LEXX |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.7M |
| IPO Year | 2009 | 2011 |
| Metric | REED | LEXX |
|---|---|---|
| Price | $1.08 | $10.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 6.7K | ★ 92.8K |
| Earning Date | 05-12-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,065,000.00 | $705,923.00 |
| Revenue This Year | $18.74 | N/A |
| Revenue Next Year | $18.00 | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.73 | $0.35 |
| 52 Week High | $5.97 | $12.89 |
| Indicator | REED | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 83.12 |
| Support Level | $0.76 | $0.65 |
| Resistance Level | $1.42 | N/A |
| Average True Range (ATR) | 0.11 | 1.01 |
| MACD | 0.04 | 0.40 |
| Stochastic Oscillator | 69.59 | 69.36 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.